|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗(pembrolizumab)与化疗治疗微卫星不稳定性高/错配修复缺陷型转移性结直肠癌的比较:KEYNOTE-177的3期研究显示文摘背景:KEYNOTE-177 (NCT02563002)是一项3期随机、开放标签的临床研究,评估了帕博利珠单抗与标准化疗±贝伐珠单抗或西妥昔单抗作为微卫星不稳定性高/错配修复缺陷(MSI-H/d MMR)型转移性结直肠癌患者一线治疗的效果和安全性。本次公布了终期PFS分析的结果。方法:共有307名由当地医疗机构评判的MSI-H/d MMR且ECOG PS评分为0或1的转移性结直肠癌患者按1:1比例随机分组接受治疗,治疗方案为一线帕博利珠单抗(200 mg,Q3W,最长治疗时限为2年),或为研究者所选择的化疗方案,包括m FOLFOX6或FOLFIRI Q2W±贝伐珠单抗或西妥昔单抗(随机选择化疗方案)。治疗终止于出现PD、无法耐受的毒性、患者/研究者决定退出治疗或完成35个周期治疗(仅对于帕博利珠单抗而言)。确诊PD后,接受化疗组患者可转入帕博利珠单抗组并接受最长为35个周期的治疗。主要终点是PFS (RECIST v1.1,中心审查)和OS。主要的次要终点包括ORR (RECIST v1.1,中心审查)和安全性。该中期分析的数据截止日期是2020年2月19日。该研究仍将继续随访评估OS。结果:截止数据纳入时,153名患者被随机分至帕博利珠单抗组,154名患者被随机分至化疗组。帕博利珠单抗组的中位随访为28.4个月(0.2~48.3个月),化疗组为27.2个月(0.8~46.6个月)。帕博利珠单抗组PFS优于化疗组(中位时间16.5个月vs. 8.2个月;HR=0.60,95%CI:0.45~0.80,P=0.0002)。帕博利珠单抗组的12个月和24个月PFS率分别为55.3%和48.3%,化疗组则相应分别为37.3%和18.6%。帕博利珠单抗组与化疗组经确认的ORR分别为43.8%与33.1%;帕博利珠单抗组与化疗组中位持续反应时间分别为未达到(2.3+~41.4+个月)和10.6个月(2.8~37.5+个月)。帕博利珠单抗组3~5级与治疗相关的不良事件(AE)发生率为22%,化疗组为66%。化疗组中有1例患者因治疗相关的AE死亡。结论:与化疗相比,帕博利珠单抗作为MSI-H/d MMR型转移性结直肠癌的一线治疗可提供具有临床意义和统计学意义的PFS获益,同时观察到较少的与治疗相关的AE,应该成为这类患者的新的标准治疗方案。 | 陈功 ANDRé T SHIU K K KIM T W | 2020 | 结直肠肛门外科2020，26，6： | 15 |
| 2 | mi R-122 negatively correlates with liver fibrosis as detected by histology and FibroScan显示文摘AIM: To investigate whether expression of selected mi RNAs obtained from fibrotic liver biopsies correlate with fibrosis stage.METHODS: Altogether, 52 patients were enrolled in the study representing various etiologic backgrounds of fibrosis: 24 cases with chronic hepatitis infections(types B, C), 19 with autoimmune liver diseases(autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, overlapping syndrome cases), and 9 of mixed etiology(alcoholic and nonalcoholic steatosis, cryptogenic cases). Severity of fibrosis was determined by both histologic staging using the METAVIR scoring system and noninvasive transient elastography. Following RNAisolation, expression levels of mi R-21, mi R-122, mi R-214, mi R-221, mi R-222, and mi R-224 were determined using Taq Man Micro RNA Assays applying mi R-140 as the reference. Selection of mi RNAs was based on their characteristic up- or downregulation observed in hepatocellular carcinoma. Relative expression of mi RNAs was correlated with fibrosis stage and liver stiffness(LS) value measured by transient elastography, as well as with serum alanine aminotransferase(ALT) level.RESULTS: The expression of individual mi RNAs showed deregulated patterns in stages F1-F4 as compared with stage F0, but only the reduced level of mi R-122 in stage F4 was statistically significant(P < 0.04). When analyzing mi RNA expression in relation to fibrosis, levels of mi R-122 and mi R-221 showed negative correlations with fibrosis stage, and mi R-122 was found to correlate negatively and mi R-224 positively with LS values(all P < 0.05). ALT levels displayed a positive correlation with mi R-21(P < 0.04). Negative correlations were observed in the fibrosis samples of mixed etiology between mi R-122 and fibrosis stage and LS values(P < 0.05), and in the samples of chronic viral hepatitis, between mi R-221 and fibrosis stage(P < 0.01), whereas mi R-21 showed positive correlation with ALT values in the samples of autoimmune liver diseases(P < 0.03). The results also revealed a strong correlation between fibrosis stage and LS values(P < 0.01) when etiology of fibrosis was not taken into account.CONCLUSION: Reduced expression of mi R-122 in advanced fibrosis and its correlation with fibrosis stage and LS values seem to be characteristic of hepatic fibrosis of various etiologies. | Tünde Halász Gábor Horváth Gabriella Pár Klára Werling András Kiss Zsuzsa Schaff Gábor Lendvai | 2015 | World Journal of Gastroenterology2015，21，25： | 11 |
| 3 | Ⅲ期结肠癌患者辅助化疗持续时间的影响研究(IDEA研究合作组):基于6项Ⅲ期随机试验数据的前瞻性汇集分析最终结果显示文摘背景:这项前瞻性汇集分析基于6项Ⅲ期随机试验结果,旨在探讨Ⅲ期结肠癌患者接受3个月与6个月辅助化疗后关于无病生存期的劣效性。汇集分析结果未显示非劣效性。在此,我们报告最终的总体生存结果。方法:在这项前瞻性汇集分析中,我们纳入的Ⅲ期结肠癌患者年满18周岁,东部合作肿瘤小组(Eastern Cooperative Oncology Group,ECOG)评分为0~1分,并于2007年6月20日至2015年12月31日在12个国家/地区入组研究(包括CALGB/SWOG 80702、IDEA France、SCOT、ACHIEVE、TOSCA与HORG试验),接受了任一治疗(改良意向性治疗)。患者在医师的建议下,接受为期3个月或6个月的每2周重复一次的FOLFOX方案化疗(氟尿嘧啶+亚叶酸钙+奥沙利铂)或每3周重复一次的CAPOX方案化疗(卡培他滨+奥沙利铂,存在不同使用剂量与使用方法)。主要观察指标是无病生存情况(复发时间,继发性结直肠原发肿瘤,或全因死亡情况),预定次要观察指标是总生存情况(至全因死亡时间)。设定非劣效性界值为HR=1.11。 | 张荣欣 陈功 ANDRÉ T MEYERHARDT J IVESON T | 2021 | 结直肠肛门外科2021，27，1： | 9 |
| 4 | Irritable bowel syndrome subtypes differ in body awareness, psychological symptoms and biochemical stress markers显示文摘AIM: To elucidate the differences in somatic, psycho-logical and biochemical pattern between the subtypes of irritable bowel syndrome (IBS). METHODS: Eighty IBS patients, 30 diarrhoea pre-dominant (D-IBS), 16 constipation predominant (C-IBS) and 34 alternating IBS (A-IBS) underwent physi-otherapeutic examinations for dysfunctions in body movements and awareness and were compared to an apparently healthy control group (AHC). All groups an-swered questionnaires for gastrointestinal and psycho-logical symptoms. Biochemical variables were analysed in blood. RESULTS: The D-IBS group showed less body aware-ness, less psychological symptoms, a more normal sense of coherence and psychosocial rating as well as higher C-peptide values. C-IBS had a higher degree of body dysfunction and psychological symptoms, as well as the lowest sense of coherence compared to controls and D-IBS. They also demonstrated the most elevated prolactin levels. A-IBS had the lowest degree of body disturbance, deteriorated quality of life and affected bi-ochemical pattern. All subtypes had higher pain scores compared to controls. In addition they all had signifi -cantly increased triglycerides and elevated morning cortisol levels, however, without statistical signifi cance compared with the controls.CONCLUSION: IBS subtypes showed different pro-files in body awareness, somatic and psychological symptoms and in biochemical variables. D-IBS differed compared to the other groups by lowered body aware-ness, less psychological symptoms and a higher sense of coherence and elevated C-peptide values. C-IBS and A-IBS subtypes suffered more from depression and anxiety, associated with a lower quality of life. These differences may be important and will be taken into account in our treatment of these patients. | Elsa M Eriksson Kristina I Andrén Henry T Eriksson Gran K Kurlberg | 2008 | World Journal of Gastroenterology2008，14，31： | 7 |
| 5 | The influence of transforming growth factor‐α, cyclooxygenase‐2, matrix metalloproteinase (MMP)‐7, MMP‐9 and CXCR4 proteins involved in epithelial–mesenchymal transition on overall survival of patients with gastric cancer显示文摘 | Marcello Ferretti Fanelli Ludmilla T Domingos Chinen Maria Dirlei Begnami Wilson Luis Costa José Humberto T Fregnami Fernando A Soares André Luis Montagnini | 2012 | Histopathology2012，，2： | 2 |
| 6 | Elevated miR-33a and miR-224 in steatotic chronic hepatitis Cliver biopsies显示文摘AIM:To assess the expression of selected microRNAs(miRNA) in hepatitis C,steatotic hepatitis C,noninfected steatotic and normal liver tissues.METHODS:The relative expression levels of miR-21,miR-33 a,miR-96,miR-122,miR-125 b,miR-221 and miR-224 were determined in 76 RNA samples isolated from 18 non-steatotic and 28 steatotic chronic hepatitis C(CHC and CHC-Steatosis,respectively) cases,18 non-infected,steatotic liver biopsies of metabolic origin(Steatosis) and 12 normal formalin-fixed paraffin-embedded liver tissues using TaqMan MicroRNA Assays.All CHC biopsy samples were obtained prior to initiating therapy.Patients' serum biochemical values,which included glucose,triglyceride,cholesterol,alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma-glutamyl-transferase(GGT),alkaline phosphatase(AP),were obtained and correlated with relative miRNA expression.RESULTS:When compared with control non-infected liver samples,miR-122 and miR-221 levels were reduced in CHC-Steatosis(P < 0.03) and in CHC,CHCSteatosis and Steatosis(P < 0.01).Alternatively,the expression of miR-33 a and miR-224 were elevated in CHC-Steatosis and Steatosis in comparison to control tissue(P < 0.01).The levels of miR-33 a and miR-224 in CHC-Steatosis(P < 0.02) and miR-224 in Steatosis(P < 0.001) were increased in comparison to CHC samples.By contrast,the expression of miR-21 did not differ statistically between diseased and normal liver samples.Levels of miR-33 a correlated negatively with serum AST and AP levels in Steatosis as well as with necroinflammatory grade in CHC,whereas miR-21 correlated positively with AST in Steatosis and displayed negative correlation with triglyceride level in CHC-Steatosis.In contrast,miRNA levels were not correlated with ALT,GGT,cholesterol levels or fibrosis stage.CONCLUSION:Differences in miRNA expression were observed between CHC and steatotic CHC,CHC and steatotic liver,but not between steatotic CHC and steatotic liver of metabolic origin. | Gabor Lendvai Katalin Jármay Gizella Karácsony Tünde Halász Ilona Kovalszky Kornélia Baghy Tibor Wittmann Zsuzsa Schaff András Kiss | 2014 | World Journal of Gastroenterology2014，20，41： | 2 |
| 7 | Therapeutic drug monitoring in patients with inflammatory bowel disease显示文摘Thiopurine analogs and anti-tumor necrosis factor(TNF)agents have dramatically changed the therapeutics of inflammatory bowel diseases(IBD),improving short and long-term outcomes.Unfortunately some patients do not respond to therapy and others lose response over time.The pharmacokinetic properties of these drugs are complex,with high inter-patient variability.Thiopurine analogs are metabolized through a series of pathways,which vary according to the patients’pharmacogenetic profile.This profile largely determines the ratios of metabolites,which are in turn associated with likelihoods of clinical efficacy and/or toxicity.Understanding these mechanisms allows for manipulation of drug dose,aiming to reduce the development of toxicity while improving the efficacy of treatment.The efficacy of anti-TNF drugs is influenced by many pharmacodynamic variables.Several factors may alter drug clearance,including the concomitant use of immunomodulators(thiopurine analogs and methotrexate),systemic inflammation,the presence of anti-drug antibodies,and body mass.The treatment of IBD has evolved with the understanding of the pharmacologic profiles of immunomodulating and TNF-inhibiting medications,with good evidence for improvement in patient outcomesobserved when measuring metabolic pathway indices.The role of routine measurement of metabolite/drug levels and antibodies warrants further prospective studies as we enter the era of personalized IBD care. | Andres J Yarur Maria T Abreu Amar R Deshpande David H Kerman Daniel A Sussman | 2014 | World Journal of Gastroenterology2014，20，13： | 2 |
| 8 | Effect of Cyclosporine on Left Ventricular Remodeling After Reperfused Myocardial Infarction显示文摘 | Nathan Mewton Pierre Croisille Gerald Gahide Gilles Rioufol Eric Bonnefoy Ingrid Sanchez Thien Tri Cung Catherine Sportouch Denis Angoulvant Gérard Finet Xavier André-Fou?t Geneviève Derumeaux Christophe Piot Hélène Vernhet Didier Revel Michel Ovize | 2010 | Journal of the American College of Cardiology2010，，12： | 2 |
| 9 | Effects of hydrogen peroxide and nitric oxide on both salt and heat stress tolerance in rice显示文摘 | Akio Uchida Andre T Jagendorf Takashi Hibino Teruhiro Takabe Tetsuko Takabe | 2002 | Plant Science2002，，3： | 2 |
| 10 | Relationship between diabetes mellitus and cataract in Hungary显示文摘AIM:To examine the coexistence of diabetes mellitus(DM)and cataract in Hungary.The effects of DM on the cataract surgical results were also in the focus of analysis.METHODS:Statistical data analysis of the results of the Rapid Assessment of Avoidable Blindness with Diabetic Retinopathy(RAAB+DR)module conducted in Hungary in 2015.This cross-sectional,population-based,national survey included 3523 people aged 50 years and over.Participants of the survey were examined on-site.Visual acuity,main cause for visual impairment(using direct and indirect ophthalmoscopes),in case of best corrected visual acuity(BCVA)≤0.5 and blood glucose level(random test with glucometer)were examined.RESULTS:The prevalence of cataract was 23.4%,and DM was 20.0%.The occurrence of cataract steadily increased with age.Among the examined participants with DM,the prevalence of cataract was significantly(P=0.012)higher(+35%)than that in non-diabetic subjects(29.5%vs 21.8%).Following aging(OR=15.2%,P<0.001),DM proved to be the most independent influencing risk factor(OR=49.9%,P<0.001).The presence of DM was neither an influencing factor for complications of cataract surgery,nor for postoperative visual acuity.CONCLUSION:DM appears to be one of the main risk factors for developing cataract.Other risk factors,such as age,sex and environment also play an influencing role.Diabetes does not seem to affect the occurrence of cataract surgical complications. | Anita Pék Dorottya Szabó Gábor LászlóSándor Gábor Tóth András Papp Zoltán Zsolt Nagy Hans Limburg János Németh | 2020 | International Journal of Ophthalmology(English edition)2020，13，5： | 2 |
| 11 | Splenic and portal venous obstruction in chronic pancreatitis显示文摘 | Pr. Pierre Bernades André Baetz Philippe Lévy Jacques Belghiti Yves Menu Fran?ois Fékété | 1992 | Digestive Diseases and Sciences1992，，3： | 2 |
| 12 | 脊柱手术术后放置引流管24h抗生素预防性治疗的恰当性:一项前瞻性随机对照研究显示文摘脊柱手术术后感染率随手术复杂程度的不同而有所差异,手术时间延长、内固定使用、肌肉切开和牵拉以及分期手术等,都可能导致感染率上升。目前在脊柱手术术后数天内放置引流管已属常规操作,既可降低血肿的发生风险,又能减少伤口积液,降低感染率,但研究表明,长期放置引流管的细菌感染率高于短期放置。24 h抗生素预防使用目前已成为骨科术后的规范程序,但事实上,很多脊柱骨科医生术后会在引流管放置期间持续使用抗生素,以预防细菌通过引流管感染和播散。 | Takemoto RC Lonner B Andres T 胡玮 尹庆水 | 2015 | 中国骨科临床与基础研究杂志2015，7，5： | 2 |
| 13 | Phase Ⅱ study of oxaliplatin,fluorouracil,and folinic acid in locally advanced or metastatic gastric cancer patients显示文摘 | Louvet C André T Tigaud JM | 2002 | Journal of Clinical Oncology2002，，23： | 2 |
| 14 | Cell Therapy Based on Adipose Tissue-Derived Stromal Cells Promotes Physiological and Pathological Wound Healing显示文摘 | T G. Ebrahimian F Pouzoulet C Squiban V Buard M André B Cousin P Gourmelon M Benderitter L Casteilla R Tamarat | 2009 | Arteriosclerosis, Thrombosis, and Vascular Biology2009，，4： | 2 |
| 15 | Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary显示文摘AIM: To analyze the serum levels of retinoids and Leiden mutation in patients with esophageal, gastric, liver,pancreatic, and colorectal cancers.METHODS: The changes in serum levels of retinoids (vitamin A, α- and β-carotene, α- and β-cryptoxanthin,zeaxanthin, lutein) and Leiden mutation were measured by high liquid performance chromatography (HPLC)and polymerase chain reaction (PCR) in 107 patients (70 males/37 females) with esophageal (0/8), gastric (16/5), liver (8/7), pancreatic (6/4), and colorectal (30/21including 9 patients suffering from in situ colon cancer)cancer. Fifty-seven healthy subjects (in matched groups)for controls of serum retinoids and 600 healthy blood donors for Leiden mutation were used.RESULTS: The serum levels of vitamin A and zeaxanthin were decreased significantly in all groups of patients with gastrointestinal (GI) tumors except for vitamin A in patients with pancreatic cancer. No changes were obtained in the serum levels of α- and β-carotene,α- and β-cryptoxanthin, zeaxanthin, lutein in patients with GI cancer. The prevalence of Leiden mutation significantly increased in all groups of patients with GI cancer.CONCLUSION: Retinoids (as environmental factors)are decreased significantly with increased prevalence of Leiden mutation (as a genetic factor) in patients before the clinical manifestation of histologically different (planocellular and hepatocellular carcinoma, and adenocarcinoma) GI cancer. | Gyula Mózsik Gy(o|¨)rgy Rumi András D(o|¨)m(o|¨)t(o|¨)r Mária Figler Beáta Gasztonyi El(?)d Papp Alajos Pár Gabriella Pár József Belágyi Zoltán Matus Béla Melegh | 2005 | World Journal of Gastroenterology2005，11，48： | 2 |
| 16 | The pharmacokinetics of 750 μg levonorgestrel following administration of one single dose or two doses at 12 - or 24 -h in terval 显示文摘 | DOMINIQUE T ERIN G ANDRE U | 2001 | Contraception2001，64，3： | 1 |
| 17 | A Comparison of Gas and Water显示文摘 | Miehaeli W Andre B Pohl T | 1999 | Kunststoffe Plast Europe1999，89，9： | 1 |
| 18 | Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients显示文摘 | Louvet C Andre T Tigaud JM | 2002 | J Clin Oneol2002，20，23： | 1 |
| 19 | A review of GEBCOD trial of bimonthly leucovorin plus 5-fluorouracil 48h continuous infusion in advanced colorectal cancer: evolutions ofa regimen 显示文摘 | De Gramont A Louvet C Andre T | 1998 | Eur J Cancer1998，34，5： | 1 |
| 20 | VEGF, VEGF-B, VEGF-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa显示文摘 | Andre T Kotelevets L Vaillant J C | 2000 | Int J Cancer2000，86，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员